The present study provides conclusive evidence that NR5A2 is a suitable target for pancreatic cancer via a dual mechanism involving SOX2 and MYC and that a considerable fraction of PDAC tumors responded to NR5A2 inhibition, but a combination with tumor-debulking chemotherapy is needed for improved outcomes. Here, SOX2 is linked to neoplasm.